Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Samsung Epis Holdings was formed as a spin-off from Samsung Biologics in 2025 and is now the parent company overseeing Samsung Bioepis and Epis NexLab, both focused on biosimilars, innovative biologics and platform technologies; its main subsidiary Samsung Bioepis has commercialized 11 biosimilars and aims to expand to over 20 assets, covering immunology, oncology, ophthalmology, and hematology, with strong clinical evidence and global access
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Samsung Epis Holdings.